Hunan Jingfeng Pharmaceutical Asset Resilience Ratio
Hunan Jingfeng Pharmaceutical asset resilience ratio. Hunan Jingfeng Pharmaceutical (000908) has an Asset Resilience Ratio of 0.38% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hunan Jingfeng Pharmaceutical (000908) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hunan Jingfeng Pharmaceutical (1998–2018)
Asset resilience ratio of Hunan Jingfeng Pharmaceutical from 1998 to 2018. This chart shows how Hunan Jingfeng Pharmaceutical's Asset Resilience Ratio has changed over time. Read Hunan Jingfeng Pharmaceutical (000908) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hunan Jingfeng Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hunan Jingfeng Pharmaceutical balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥20.00 Million | 0.38% |
| Total Liquid Assets | CN¥20.00 Million | 0.38% |
Asset Resilience Insights
- Limited Liquidity: Hunan Jingfeng Pharmaceutical maintains only 0.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hunan Jingfeng Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Hunan Jingfeng Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Cosmo Pharmaceuticals N.V
F:C43 |
Drug Manufacturers - General | 10.92% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Hunan Jingfeng Pharmaceutical Asset Resilience Ratio by Year (1998–2018)
Hunan Jingfeng Pharmaceutical asset resilience ratio by year from 1998 to 2018. The table below shows the annual Asset Resilience Ratio data for Hunan Jingfeng Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.38% | CN¥20.00 Million ≈ $2.93 Million |
CN¥5.23 Billion ≈ $764.89 Million |
+0.15pp |
| 2016-12-31 | 0.23% | CN¥11.94 Million ≈ $1.75 Million |
CN¥5.13 Billion ≈ $751.27 Million |
+0.21pp |
| 2015-12-31 | 0.02% | CN¥706.00K ≈ $103.31K |
CN¥3.44 Billion ≈ $503.77 Million |
-0.29pp |
| 2009-12-31 | 0.31% | CN¥2.40 Million ≈ $351.20K |
CN¥784.81 Million ≈ $114.84 Million |
+0.21pp |
| 2007-12-31 | 0.10% | CN¥801.34K ≈ $117.26K |
CN¥814.38 Million ≈ $119.17 Million |
+0.06pp |
| 2006-12-31 | 0.04% | CN¥350.00K ≈ $51.22K |
CN¥822.47 Million ≈ $120.35 Million |
-3.49pp |
| 2005-12-31 | 3.53% | CN¥29.66 Million ≈ $4.34 Million |
CN¥840.14 Million ≈ $122.94 Million |
-2.63pp |
| 2004-12-31 | 6.16% | CN¥54.81 Million ≈ $8.02 Million |
CN¥889.56 Million ≈ $130.17 Million |
-10.65pp |
| 2003-12-31 | 16.81% | CN¥165.26 Million ≈ $24.18 Million |
CN¥983.02 Million ≈ $143.85 Million |
+16.63pp |
| 2002-12-31 | 0.18% | CN¥1.57 Million ≈ $229.79K |
CN¥866.67 Million ≈ $126.82 Million |
-8.42pp |
| 2000-12-31 | 8.60% | CN¥60.00 Million ≈ $8.78 Million |
CN¥697.92 Million ≈ $102.13 Million |
-0.07pp |
| 1999-12-31 | 8.67% | CN¥60.00 Million ≈ $8.78 Million |
CN¥691.94 Million ≈ $101.25 Million |
-1.90pp |
| 1998-12-31 | 10.57% | CN¥50.00 Million ≈ $7.32 Million |
CN¥473.15 Million ≈ $69.24 Million |
-- |
About Hunan Jingfeng Pharmaceutical
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more